belotecan

06/01/2010 - "As a single chemotherapy agent, belotecan was effective in treating recurrent or refractory epithelial ovarian cancer, and had acceptable toxicity. "
05/15/2011 - "This phase II study was designed to evaluate the toxicity and efficacy of belotecan combined with carboplatin in patients with recurrent epithelial ovarian cancer (EOC). "
06/01/2010 - "The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer."
08/01/2009 - "Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer."
02/01/2010 - "To compare the efficacy and toxicity between topotecan- and belotecan-based chemotherapies in recurrent epithelial ovarian cancer (EOC). "

01/01/2008 - "This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). "
10/01/2013 - "The aim of this phase II study was to investigate the efficacy and toxicity of belotecan in previously untreated elderly patients with small cell lung cancer (SCLC). "
06/01/2010 - "The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan in patients with small cell lung cancer (SCLC). "
04/01/2012 - "Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients."
04/01/2012 - "The aim of this study was to evaluate the efficacy and safety of belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). "

02/01/2012 - "Covariate analysis revealed that tumor in the liver was a significant covariate for clearance of encapsulated CKD-602 and that age significantly influenced the release rate of CKD-602 from S-CKD602. "
12/01/2007 - "S-CKD602 provides pharmacokinetic advantages in plasma, tumor, and tumor ECF compared with nonliposomal CKD-602 at 1/30th of the dose, which is consistent with the improved antitumor efficacy of S-CKD602 in preclinical studies. "
11/01/2009 - "Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies."
02/15/2009 - "Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies."
01/25/2003 - "The described method was used for the pharmacokinetic analysis of CKD-602 during clinical phase I studies, in patients with solid tumors."

01/01/2021 - "This Phase 2b study compared the efficacy and toxicity of belotecan and topotecan in recurrent ovarian cancer. "
01/01/2021 - "A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer."
01/01/2021 - "Belotecan was not inferior to topotecan in terms of overall response for recurrent ovarian cancer. "
06/01/2010 - "Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer."
06/01/2008 - "To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer. "

03/01/2009 - "The purposes of this study were to measure the cytotoxic effect of CKD-602 on oral squamous cell carcinoma (OSCC) cell lines, to evaluate the apoptotic aspect of dead cells, and to identify the signaling molecules involved in apoptosis. "
01/01/2015 - "Anticancer effects of CKD-602 (Camtobell®) via G2/M phase arrest in oral squamous cell carcinoma cell lines."
03/01/2009 - "Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines."
01/01/2015 - "In the present study, the anticancer effects of CKD-602 on the following three human oral squamous cell carcinoma (OSCC) cell lines originating from Korean cancer patients: YD-8 (tongue), YD-9 (buccal mucosa) and YD-38 (lower gingiva) were analyzed. "
02/01/2019 - "The purpose of this study was to evaluate the synergistic apoptotic effect of CKD-602 in combination with cisplatin on different p53 statuses of oral squamous cell carcinoma (OSCC) cell lines, YD-8, YD-9, and YD-38. "